- ... 19 248-3000 The progress of RETROVIR brand zidovudine (formerly known as AZT) as a treatment for ... Application to FDA. The FDA approves RETROVIR brand zidovudine (AZT) as a treatment for advanced ARC and ...
- ... treatment of A1DS virus infection. A single drug, zidovudine t also called AZT, has been shown to ...
- AIDS, the Surgeon General, and the Politics of Public Health | C. Everett Koop - Profiles in Science... was not curable. With the advent of AZT (zidovudine, formerly called azidothymidine) in 1986, and especially with ...
- ... levels: application to an AIDS clinical trial of zidovudine. Lim LL. Biometrics 1992 Jun; 48(2):619- ... 45(l):21-7 Pharmacists1 activities in monitoring zidovudine therapy in an AIDS clinic. Walji N, et ...
- ... 47 (74 ref.) Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus ( ... Defic Syndr 1991; 4(10): 1010-4 Modeling zidovudine therapy: a cost-effectiveness analysis. Paltiel AD, et ...
- ... 6):1015-8 Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. Oddone EZ, et ... Hosp Formul 1993 Oct;28(10):821, 824 Zidovudine therapy and health resource utilization in AIDS. Moore ...
- ... the . price cut reduccs the wholesale | Price of zidovudine from $1.50 per , capsule to $1.20. ‘ ... 200 wholesale and $2.684 retail. Last year. zidovudine gencrated - $113 million tn sales for Burroughs Wellcome, ...
- ... American Embassy, Cairo, Egypt. ANTI-RETROVIRAL THERAPY: THE ZIDOVUDINE EXPERIENCE IN ADULTS Dr. A.A.M. Aulaqi ... H29. AA.335. ) ; 25 ANTI-RETROVIRAL THERAPY: THE ZIDOVUDINE (RETROVIR) EXPERIENCE IN ADULTS A.A.M. Aulaqi, ...
- ... plasma. Biochim Biophys Acta. 1962;704: Lithium for Zidovudine-Induced Neutropenia in AIDS To the Editor. ~We ... may be used to treat neutropenia induced by zidovudine. This assertion raises anum- ber of points with ...
- ... FFDCA): sponsor: Burroughs Wellcome Company Drug Name: Generic - zidovudine Trade - Retrovir — Orphan Indication: For use in the ... peripheral blood before therapy is begun. Rationale: Retrovir (zidovudine) was approved for marketing on March 19, 1987 ...
151 results